Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 322

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 322
---
 December 31, 2024— — Additional paid-in capital281,148,253 265,650,362 Accumulated deficit(239,341,318)(224,295,186)Total stockholders' equity41,842,920 41,386,226 Total liabilities and stockholders' equity$50,681,297 $52,714,413 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

7

Table of Contents

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

Three Months Ended March 31,20252024Operating expensesResearch and development$11,471,693 $11,202,414 General and administrative4,005,642 4,116,019 Amortization of intangible asset7,317 7,317 Total operating expenses15,484,652 15,325,750 Loss from operations(15,484,652)(15,325,750)Other income (expense)Interest income438,520 804,884 Other income, net— 213,037 Net loss$(15,046,132)$(14,307,829)Net loss per share attributable to common stockholders, basic and diluted$(0.42)$(0.49)Weighted-average common shares outstanding, basic and diluted35,529,65229,370,357Other comprehensive loss:Unrealized loss from marketable securities— (306)Comprehensive Loss$(15,046,132)$(14,308,135)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

8

Table of Contents

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Class A Common StockClass B Common StockAdditionalPaid-In CapitalAccumulated OtherComprehensive LossAccumulatedDeficitTotalStockholders' EquitySharesPar ValueSharesPar ValueBalance at December 31, 202431,050,448$31,050 —$— $265,650,362 $— $(224,295,186)$41,386,226 Issuance of common stock under at-the-market offering, net of issuance costs4,836,8044,837 —— 13,671,830 — — 13,676,667